Breast Cancer Clinical Trial
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Summary
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.
Exclusion Criteria:
Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Birmingham Alabama, 35233, United States
Birmingham Alabama, 35249, United States
Birmingham Alabama, 35249, United States
Stanford California, 94305, United States
Stanford California, 94305, United States
Stanford California, 94305, United States
Stanford California, 94305, United States
Detroit Michigan, 48201, United States
Detroit Michigan, 48201, United States
Chapel Hill North Carolina, 27514, United States
Chapel Hill North Carolina, 27599, United States
Bruxelles , 1000, Belgium
Charleroi , 6000, Belgium
Milano , 20141, Italy
Barcelona , 08908, Spain
Madrid , 28041, Spain
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.